About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Georgia | 19,050 Studies Near You | Clareo Health

Clinical Trials LocationsGeorgia

Clinical Trials in Georgia

Discover 19,050 clinical trials near Georgia. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 8621-8640 of 19,050 trials

COMPLETEDNA14 miles

Formula Tolerance of Term Infants

NCT04915937

To assess the effects of infant formula with oligosaccharides on symptoms of formula intolerance in healthy, term infants

Gastro-Intestinal Tolerance

Abbott Nutrition45 participantsStarted Jul 2021

Phoenix, Arizona, United States • Miami, Florida, United States • Macon, Georgia, United States +9 more locations

COMPLETEDPhase 249 miles

An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus

NCT03252587

This study will investigate BMS-986165 to assess its effects in participants with systemic lupus erythematosus (SLE).

Systemic Lupus Erythematosus

Bristol-Myers Squibb363 participantsStarted Sep 2017

Birmingham, Alabama, United States • Little Rock, Arkansas, United States • El Cajon, California, United States +189 more locations

Find Trials by Condition in Georgia

Breast Cancerin Georgia Lung Cancerin Georgia Prostate Cancerin Georgia Colorectal Cancerin Georgia Melanomain Georgia Leukemiain Georgia Lymphomain Georgia Pancreatic Cancerin Georgia Ovarian Cancerin Georgia Brain Cancerin Georgia Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 363 miles

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03945188

The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.

Ulcerative Colitis

Arena Pharmaceuticals433 participantsStarted Jun 2019

Dothan, Alabama, United States • Sun City, Arizona, United States • Lancaster, California, United States +312 more locations

COMPLETEDPhase 365 miles

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)

NCT04249076

Cataract surgery is one of the most common surgical procedures performed worldwide. In fact, in 2017, 3.8 million cataracts procedures were performed in the US. Despite of surgical advances, pain and inflammation after ophthalmic surgery continues to be a burden on both patients and physicians. The treatment of postoperative pain is essential for hospitalized patients, but it is even more important for patients who are treated on an outpatient basis. This study will compare the efficacy and safety of clobetasol propionate ophthalmic nanoemulsion 0.05% to placebo, when administering one drop four times a day during 14 days after routine unilateral cataract surgery. Participants will undergo routine cataract surgery according to the ophthalmologist's normal procedures. Overall, 210 participants are planned to take part in the study. They will be screened across 20 centers in the US. Participants who experience postoperative inflammation on the first day following routine cataract surgery and who meet all other eligibility criteria will be randomly assigned by chance to one of two study groups in a 2:1 ratio to receive either clobetasol propionate ophthalmic nanoemulsion 0.05 % (N=140) or placebo (N=70) for the treatment of inflammation and pain associated with cataract surgery. Six (6) study visits are planned: Visit -1 (Screening), Visit 1 (Baseline; 24h after the surgery), Visit 2 (Day 3), Visit 3 (Day 8), Visit 4 (Day 15), and Visit 5 (Day 29). The ophthalmologist will administer the first dose of the study medication 24 hours after the surgery, at the end of the Baseline visit, at the study center. Study medication will be then dispensed to patients for self-administration during the study at a dosage of one drop four times a day, during 14 days. Direct instillation is the most efficient method for delivery to the ocular surface and is an accepted and widely used method for topical application to the eye. This study will examine effect and tolerability for 14 days of clobetasol propionate ophthalmic nanoemulsion 0.05% dosed four times a day. This study is being conducted to support an application for approval to market clobetasol propionate ophthalmic nanoemulsion 0.05% in the US for the indication of inflammation and pain after ocular surgery. The reference (comparator) product in this study, the vehicle, is expected to provide a lower efficacy rate when compared to clobetasol 0.05%.

Salvat215 participantsStarted Jun 2020

Sun City, Arizona, United States • Hemet, California, United States • Inglewood, California, United States +15 more locations

COMPLETEDNA65 miles

Integrated Stepped Care for Unhealthy Alcohol Use in HIV

NCT01410123

The study is a series of 3 linked randomized clinical trials of 6 month duration, with a total of 12 month follow-up, to evaluate the effect of Integrated Stepped Care on drinking outcomes and HIV biologic markers (including VACS index) in HIV-infected patients with unhealthy alcohol use.

Liver Diseases, AlcoholicAlcoholismHIV+1 more

Yale University319 participantsStarted Jan 2013

Washington D.C., District of Columbia, United States • Atlanta, Georgia, United States • New York, New York, United States +2 more locations

TERMINATEDPhase 265 miles

VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.

NCT04988997

A Study of Vurolenatide in Adult Patients with Short Bowel Syndrome.

Short Bowel Syndrome

9 Meters Biopharma, Inc.12 participantsStarted Jun 2021

Gainesville, Florida, United States • Atlanta, Georgia, United States • Boston, Massachusetts, United States +3 more locations

COMPLETEDPhase 365 miles

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

NCT03181932

This is a multi-center, randomized phase III study to evaluate the clinical effectiveness of AeroVanc in persistent methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis (CF).

MRSACystic Fibrosis

Savara Inc.188 participantsStarted Sep 2017

Mobile, Alabama, United States • Phoenix, Arizona, United States • Little Rock, Arkansas, United States +68 more locations

Active Not RecruitingNA65 miles

The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System

NCT04559945

prospective, non-randomized, multi-center, international clinical study is designed to confirm the safety and effectiveness of the Aveir LP System in a subject population indicated for a VVI(R) pacemaker.

Cardiac Rhythm DisorderBradycardia

Abbott Medical Devices326 participantsStarted Nov 2020

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Scottsdale, Arizona, United States +50 more locations

COMPLETEDPhase 382 miles

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

NCT03611751

The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.

Bristol-Myers Squibb1,020 participantsStarted Jul 2018

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Phoenix, Arizona, United States +202 more locations

COMPLETEDPhase 2101 miles

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

NCT02996110

The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer

Advanced Cancer

Bristol-Myers Squibb182 participantsStarted Feb 2017

New Haven, Connecticut, United States • Tampa, Florida, United States • Augusta, Georgia, United States +29 more locations

COMPLETEDPhase 2202 miles

An Extension of the TG1101-RMS201 Trial

NCT03381170

This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis

Relapsing Remitting Multiple Sclerosis

TG Therapeutics, Inc.48 participantsStarted Jun 2017

Pasadena, California, United States • Aurora, Colorado, United States • Lexington, Kentucky, United States +5 more locations

COMPLETEDPhase 3216 miles

A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A

NCT03528551

This study will look at how a known study medicine N8-GP works in previously N8-GP treated people with haemophilia A. The aim is to look at how N8-GP works during regular use. Participants will get N8-GP. N8-GP has been tested in more than 200 people with haemophilia A for several years. Participants will get an injection of N8-GP into a blood vessel, one, two or three times weekly. Participants will get more doses if they bleed or if they will need a surgery. The study will last for about 2 years. Participants will have at least 9 visits with the study doctor. If participants agree to be in this study, they will get their first injection (in this study) at the first visit. Participants will also get an injection at visit 3, 5 and 7. Participants will be trained to give all other injections themselves. Participants must not use any clotting factors other than N8-GP or any anticoagulants (blood thinners) during the study.

Congenital Bleeding DisorderHaemophilia A

Novo Nordisk A/S160 participantsStarted Apr 2018

Phoenix, Arizona, United States • Long Beach, California, United States • Iowa City, Iowa, United States +64 more locations

COMPLETED216 miles

Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation

NCT02084160

The objectives of this study are: * To evaluate the ability of the Methacetin Breath Test (MBT) to detect hepatic decompensation events * To evaluate the relationship between liver Biopsy and clinical outcome and show that the MBT has a better predictive ability of clinical outcome than liver biopsy. * To evaluate the ability of the MBT to predict each of the individual liver related complications.

Chronic Liver Disease

Meridian Bioscience, Inc.579 participantsStarted Mar 2014

Detroit, Michigan, United States • Charleston, South Carolina, United States • Richmond, Virginia, United States +1 more locations

COMPLETEDPhase 3280 miles

Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics

NCT02905825

Clinical Study to Confirm Safety and Accuracy in Detection of H. pylori with 13C-Urea Breath Test using the BreathID® Hp and BreathID® Hp Lab Systems in the Pediatric Population

Helicobacter Pylori Infection

Meridian Bioscience, Inc.54 participantsStarted May 2017

Shreveport, Louisiana, United States • Flowood, Mississippi, United States • Nashville, Tennessee, United States +3 more locations

COMPLETEDPhase 2312 miles

A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics

NCT04663282

The study is being conducted to evaluate the efficacy and safety of IND068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with one or two oral antidiabetics compared to insulin degludec QD for 16 weeks.

Type 2 Diabetes

Jiangsu HengRui Medicine Co., Ltd.179 participantsStarted Feb 2021

Huntington Park, California, United States • Lincoln, California, United States • Lomita, California, United States +32 more locations

COMPLETEDPhase 3344 miles

Bag Mode BreathID Hp Validation Versus Endoscopy in Detection of Helicobacter Pylori

NCT02010112

A new method of breath collection for testing for Helicobacter Pylori infection has been developed by Exalenz. In this study, it will be compared to the gold standard- endoscopy results to prove its accuracy.

Helicobacter Pylori Infection

Meridian Bioscience, Inc.193 participantsStarted Jan 2014

Baltimore, Maryland, United States • Chevy Chase, Maryland, United States • Detroit, Michigan, United States +6 more locations

COMPLETEDPhase 3353 miles

Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection

NCT02528721

The Exalenz Dual Mode BreathID® Hp System comprised of IDkit: Hp™ TWO and the Dual Mode BreathID® Hp test device will be used to perform a urea breath test in the initial diagnosis and post treatment monitoring of H.pylori infection in adult patients and its results will be compared to biopsy results.

Helicobacter Pylori Infection

Meridian Bioscience, Inc.282 participantsStarted Oct 2015

Tucson, Arizona, United States • Ventura, California, United States • Lafayette, Colorado, United States +10 more locations

TERMINATEDNA394 miles

Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty

NCT02327312

To evaluate the safety and effectiveness of Trabecular Micro-Bypass stents (two stents per study eye) vs. laser trabeculoplasty, in subjects with open angle glaucoma

Primary Open-Angle Glaucoma

Glaukos Corporation91 participantsStarted Dec 2014

Glendale, Arizona, United States • Fayetteville, Arkansas, United States • Hemet, California, United States +6 more locations

TERMINATEDNA543 miles

Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® Device

NCT04595903

This is an Early Feasibility Study (EFS) investigating the use of the Hemopurifier® in the treatment of SARS-CoV-2 Virus Disease (COVID-19).

Aethlon Medical Inc.1 participantsStarted Jun 2022

Irvine, California, United States • Loma Linda, California, United States • Newport Beach, California, United States +6 more locations

COMPLETEDPhase 2727 miles

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

NCT03873493

The main objective of this study is to evaluate the efficacy of the combination of venetoclax plus ibrutinib for treating adults with T-cell prolymphocytic leukemia (T-PLL).

LeukemiaT-cell Prolymphocytic Leukemia (T-PLL)Cancer

AbbVie14 participantsStarted Jan 2020

Boston, Massachusetts, United States • Rochester, Minnesota, United States • Houston, Texas, United States +12 more locations

PreviousPage 432 of 953Next

in Georgia

Heart Diseasein Georgia